Active, not recruitingPhase 2NCT04220021
Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD
Studying Amyotrophic lateral sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Florida
- Principal Investigator
- Laura Ranum, PhDUniversity of Florida
- Intervention
- Metformin(drug)
- Enrollment
- 41 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2020 – 2026
Study locations (1)
- UF Health at the University of Florida, Gainesville, Florida, United States
Collaborators
ALS Association · United States Department of Defense
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04220021 on ClinicalTrials.govOther trials for Amyotrophic lateral sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07401186Stimulation-Based Modulation of Spinal and Cortical Sensory PathwaysPeter C. Gerszten, MD
- RECRUITINGNCT07467187Invasive Home Ventilation in DenmarkRigshospitalet, Denmark
- RECRUITINGNCT07502677Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral SclerosisRoyal Brompton & Harefield NHS Foundation Trust
- RECRUITINGNANCT07446114Functional Outcomes and Control Using Synchron BCI - CanadaSynchron, Inc.
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT07410806HEALEY ALS Platform Trial - Regimen I NUZ-001Merit E. Cudkowicz, MD
- ENROLLING BY INVITATIONNANCT07298486Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALSNova Southeastern University
- ACTIVE NOT RECRUITINGPHASE1NCT07204977Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)National Institute of Neurological Disorders and Stroke (NINDS)
- RECRUITINGPHASE3NCT07322003Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALSPrilenia